The company was founded in 2003 with the aim of implementing fundamental and applied tasks in the field of bioregulation and introducing into medical practice the results of experimental and clinical research into a new class of drugs, peptide bioregulators.
Garmonia LLC performs a full cycle of operations from the drug development and research to mass production and marketing support of drugs and parapharmaceutics.
The company's key profile is the search, design and experimental study of peptide drugs with high pharmacological activity and without any analogues in the world in some cases.
Several decades of work have resulted in the creation of special preparations which have no analogues in both our country and abroad as far as their action is concerned.
The company is engaged in research and production of fundamentally new medical and parapharmaceutical products. The company's activities are based on innovative approaches to the preservation of human health and youth.
The company employees are the authors of a number of drugs approved for use by the Russian Ministry of Health, i.e. Timalin, Timogen, Epitalamin, Prostatilen, Cortexin and Retinalamin.